Saturday 17 October 2026
Export BIOA’s income statement to Excel — free account
BioAge Labs, Inc.
BIOA Healthcare Drug Manufacturers Specialty & Generic
BioAge Labs, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.0 million. In the quarter to June 2026, revenue grew 1.62%, EPS grew 3.33%, free cash flow grew 2.68% and total debt fell 83.6%, each against the same quarter a year earlier.
4.82
0.53
−9.91%
Follow BIOA
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 3.85 | 2.88 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 26.62 | 14.46 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 60 | 64 | 62 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.15 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | 9 | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | 100.00 | |||||
| EBT | — | — | — | — | — | — | — | (64) | (71) | (81) | |||||
| EBT margin, % | — | — | — | — | — | — | — | 0.00 | 0.00 | (896.11) | |||||
| Net income | — | — | — | — | — | — | — | (64) | (71) | (81) | |||||
| Depreciation | — | — | — | — | — | — | — | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.25 | ||||
| Earnings | — | — | — | — | — | — | — | (38.17) | (6.63) | (2.24) | |||||
| Cash flow | — | — | — | — | — | — | — | (22.33) | (4.80) | (2.27) | |||||
| Capex | — | — | — | — | — | — | — | (0.10) | (0.03) | (4.33) | |||||
| Free cash flow | — | — | — | — | — | — | — | (22.43) | (4.84) | (6.60) | |||||
| Book value | — | — | — | — | — | — | — | (103.66) | 30.12 | 7.57 | |||||
| Shares, m | — | — | — | — | — | — | — | 2 | 11 | 36 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | — | — | 52.85 | |||||
| P/B | — | — | — | — | — | — | — | — | — | 1.75 | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | 22.01 | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | (0.84) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (37) | (52) | (82) | ||||
| Capex | — | — | — | — | — | — | — | 0 | 0 | (155) | |||||
| Free cash flow | — | — | — | — | — | — | — | (38) | (52) | (237) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | (33) | 329 | 267 | ||||
| Total debt | — | — | — | — | — | — | — | 14 | 9 | 3 | |||||
| Net debt | — | — | — | — | — | — | — | (11) | (346) | (278) | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | (173) | 323 | 272 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (37.02) | (24.68) | ||||
| ROIC | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | — | — | 0.00 | (94.98) | (27.09) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
BioAge Labs, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| TKNO Alpha Teknova, Inc. | $408.0M | — (loss-making) | — (loss-making) | +18.45% (above 0%: growing) | n/m | +74.18% (above 0%: growing) | 40.09% | (23.72%) | Compare |
| EBS Emergent Biosolutions Inc. | $368.1M | — (loss-making) | — (loss-making) | +66.29% (above 0%: growing) | n/m | −47.68% (below 0%: shrinking) | 58.56% | (53.39%) | Compare |
| CGC Canopy Growth Corporation | $311.2M | — (loss-making) | — (loss-making) | +12.41% (above 0%: growing) | n/m | −117.60% (below 0%: shrinking) | 27.40% | (27.24%) | Compare |
| ANIK Anika Therapeutics Inc. | $276.9M | — (loss-making) | — (loss-making) | +15.56% (above 0%: growing) | n/m | +61.58% (above 0%: growing) | 65.15% | 9.06% | Compare |
| ACB Aurora Cannabis Inc. | $265.8M | — (loss-making) | — (loss-making) | −31.15% (below 0%: shrinking) | n/m | −293.56% (below 0%: shrinking) | 52.73% | (12.92%) | Compare |
| BIOA BioAge Labs, Inc. | $245.6M | — (loss-making) | — (loss-making) | +1.62% (above 0%: growing) | n/m | +2.68% (above 0%: growing) | 100.00% | (1,196.78%) | |
| LFCR Lifecore Biomedical, Inc. | $244.1M | — (loss-making) | — (loss-making) | −6.25% (below 0%: shrinking) | n/m | −117.03% (below 0%: shrinking) | 35.34% | 7.51% | Compare |
| SIGA Siga Technologies Inc. | $229.2M | — (loss-making) | 28.7× | −49.45% (below 0%: shrinking) | −66.00% (below 0%: shrinking) | −75.95% (below 0%: shrinking) | 57.17% | 33.91% | Compare |
| AKBA Akebia Therapeutics, Inc. | $192.7M | — (loss-making) | — (loss-making) | −21.36% (below 0%: shrinking) | n/m | −88.99% (below 0%: shrinking) | 78.78% | (12.88%) | Compare |
| Median of peers | $271.4M | — | — | +3.08% | — | −82.47% | 54.95% | (12.90%) |
BioAge Labs, Inc. (BIOA) key facts
- BioAge Labs, Inc. (BIOA) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
- BioAge Labs, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.0 million.
- As of October 16, 2026, BIOA traded at $4.82, a market capitalization of $245.6 million.
- Return on equity was −27.1% and debt-to-equity 0.00.
- Its Altman Z-score is 10.98 (safe zone) for fiscal 2025.